Login to Your Account

To Gaucher's and Beyond

Big Pharma Moving into Small Markets Bodes Well for Biotech

By Trista Morrison

Monday, December 7, 2009
Pfizer Inc. ventured out of its comfort zone last week, stepping away from the world of primary care blockbusters like Lipitor (atorvastatin), Celebrex (celecoxib) and Viagra (sildenafil) and into the historically biotech territory of ultra-orphan diseases.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription